The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics

作者: Jiagen Wen , Meizi Zeng , Zhaoqian Liu , Honghao Zhou , Heng Xu

DOI: 10.1016/J.JPHS.2018.11.007

关键词: PharmacokineticsMetforminInsulinMedicineSide effectPharmacodynamicsPharmacologyCrossover studyCmaxTelmisartan

摘要: Abstract Metformin is the most widely used drug among type 2 diabetes mellitus patients. However, interaction on metformin will influence its glucose-lowering effect or increase side of lactic acidosis. In this study, a randomized, two-stage, crossover study was conducted to unveil potential between and anti-hypertension drug, telmisartan. Totally, 16 healthy Chinese male volunteers were enrolled. Blood samples from various time-points after adminstration analyzed for quantification. Oral glucose tolerance test (OGTT) 2 h administration. The AUC0-12 Cmax in subjects co-administrated with telmisartan significantly lower than placebo. geometric mean ratios (value plus phase/value placebo phase) 0.7972 (90%CI: 0.7202–0.8824) 0.8336 0.7696–0.9028), respectively. Moreover, co-administration increased plasma concentrations both insulin at 0.5 h since OGTT (7.64 ± 1.86 mmol/l·min vs 6.77 ± 0.83 mmol/l·min, P = 0.040; 72.91 ± 31.98 μIU/ml·min 60.20 ± 24.20 μIU/ml·min, P = 0.037), though AUC showed no significant difference. These findings suggested that had Pharmacokinetics groups, moderate.

参考文章(29)
Wim J. Tamminga, Joachim Stangier, Jan H. G. Jonkman, Frans A. E. Sollie, Sjoerd P. van Marle, Pierre A. M. Peeters, Dietrich Türck, Jochen Schmid, Aalt Verhagen, Heinz Switek, Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. The Journal of Clinical Pharmacology. ,vol. 40, pp. 1312- 1322 ,(2000) , 10.1177/009127000004001202
Asuka Shiota, Michio Shimabukuro, Daiju Fukuda, Takeshi Soeki, Hiromi Sato, Etsuko Uematsu, Yoichiro Hirata, Hirotsugu Kurobe, Hiroshi Sakaue, Yutaka Nakaya, Hiroaki Masuzaki, Masataka Sata, Activation of AMPK–Sirt1 pathway by telmisartan in white adipose tissue: A possible link to anti-metabolic effects European Journal of Pharmacology. ,vol. 692, pp. 84- 90 ,(2012) , 10.1016/J.EJPHAR.2012.07.026
Anthony H. Barnett, Stephen C. Bain, Paul Bouter, Bengt Karlberg, Sten Madsbad, Jak Jervell, Jukka Mustonen, Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. The New England Journal of Medicine. ,vol. 351, pp. 1952- 1961 ,(2004) , 10.1056/NEJMOA042274
Hisato Takagi, Takuya Umemoto, A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients Journal of The American Society of Hypertension. ,vol. 8, pp. 578- 592 ,(2014) , 10.1016/J.JASH.2014.05.006
Tao Pang, Li-xin Sun, Tao Wang, Zhen-zhou Jiang, Hong Liao, Lu-yong Zhang, Telmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPARγ and the Akt/GSK-3β pathway. Acta Pharmacologica Sinica. ,vol. 35, pp. 727- 737 ,(2014) , 10.1038/APS.2013.199
Dmitri Kirpichnikov, Samy I. McFarlane, James R. Sowers, Metformin: an update. Annals of Internal Medicine. ,vol. 137, pp. 25- 33 ,(2002) , 10.7326/0003-4819-137-1-200207020-00009
P. J. Pentik�inen, P. J. Neuvonen, Aneri Penttil�, Pharmacokinetics of metformin after intravenous and oral administration to man. European Journal of Clinical Pharmacology. ,vol. 16, pp. 195- 202 ,(1979) , 10.1007/BF00562061
Johanna Müller, Katrin S. Lips, Linda Metzner, Reinhard H.H. Neubert, Hermann Koepsell, Matthias Brandsch, Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochemical Pharmacology. ,vol. 70, pp. 1851- 1860 ,(2005) , 10.1016/J.BCP.2005.09.011
Sylvia Deppe, Rainer H Böger, Johanna Weiss, Ralf A Benndorf, Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties Expert Opinion on Drug Metabolism & Toxicology. ,vol. 6, pp. 863- 871 ,(2010) , 10.1517/17425255.2010.494597